Encorafenib/Binimetinib in BRAF V600–Mutated Melanoma: COLUMBUS Trial Survival Update
Posted: Wednesday, March 18, 2020
According to an updated analysis of the phase III COLUMBUS trial, presented in the European Journal of Cancer, the use of encorafenib plus binimetinib may result in long-term benefits for patients with advanced BRAF V600–mutated melanoma. The findings showed an improvement in both overall and progression-free survival in patients treated with encorafenib/binimetinib, compared with vemurafenib alone, concluded Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, and colleagues.
“Based on subgroup analysis and multivariable regression modeling to account for prespecified baseline covariates, [encorafenib plus binimetinib] showed consistent improvement relative to [vemurafenib] across a broad range of patients,” the authors said.
In part I of the trial, the authors enrolled 577 patients with advanced or metastatic BRAF V600–mutant melanoma who were untreated or experienced disease progression after first-line immunotherapy. The patients were treated with encorafenib plus binimetinib, vemurafenib, or encorafenib alone.
Among those treated with encorafenib alone, encorafenib plus binimetinib, or vemurafenib, the investigators reported that 113, 116, and 138 patients, respectively, died. Patients treated with encorafenib plus binimetinib demonstrated a median overall survival of 33.6 months, compared with 23.5 months for those who received encorafenib alone and 16.9 months for those who received vemurafenib alone. Additionally, the use of encorafenib plus binimetinib decreased the risk of death by 39% when compared with vemurafenib.
The updated median progression-free survival was 14.9 months with encorafenib plus binimetinib, 9.6 months with encorafenib alone, and 7.3 months with vemurafenib. The authors noted that landmark overall survival and progression-free survival outcomes demonstrated “consistent” results for each year analyzed.
Disclosure: For full disclosures of the study authors, visit ejcancer.com.